Cargando…

Anakinra as a potential alternative in the treatment of severe acute respiratory infection associated with SARS-CoV-2 refractory to tocilizumab()

SARS-CoV-2 is a new RNA virus which causes coronavirus disease 2019 (COVID-19), declared a pandemic by the World Health Organization (WHO). It triggers an atypical pneumonia that can progress to multiorgan failure. COVID-19 can cause dysregulation of the immune system, triggering an inflammatory res...

Descripción completa

Detalles Bibliográficos
Autores principales:	Figuero-Pérez, Luis, Olivares-Hernández, Alejandro, Escala-Cornejo, Roberto A., Terán-Brage, Eduardo, López-Gutiérrez, Álvaro, Cruz-Hernández, Juan J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier España, S.L.U. and Sociedad Española de Reumatología y Colegio Mexicano de Reumatología. 2021
Materias:	Special Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7561306/ https://www.ncbi.nlm.nih.gov/pubmed/34823820 http://dx.doi.org/10.1016/j.reumae.2020.06.008

Ejemplares similares

Anakinra, una alternativa potencial en el tratamiento de la infección respiratoria grave por SARS-CoV-2 refractaria a tocilizumab
por: Figuero-Pérez, Luis, et al.
Publicado: (2021)

Use of anakinra in the treatment of SARS-CoV-2 severe respiratory infection()
por: Figuero-Pérez, Luis, et al.
Publicado: (2023)

Uso de anakinra en el tratamiento de la infección respiratoria grave por SARS-CoV-2
por: Figuero-Pérez, Luis, et al.
Publicado: (2023)

Response to Treatment with an Anti-Interleukin-6 Receptor Antibody (Tocilizumab) in a Patient with Hemophagocytic Syndrome Secondary to Immune Checkpoint Inhibitors
por: Olivares-Hernández, Alejandro, et al.
Publicado: (2021)

Resistance to Immune Checkpoint Inhibitors Secondary to Myeloid-Derived Suppressor Cells: A New Therapeutic Targeting of Haematological Malignancies
por: Olivares-Hernández, Alejandro, et al.
Publicado: (2021)

Anakinra as a potential alternative in the treatment of severe acute respiratory infection associated with SARS-CoV-2 refractory to tocilizumab: comment()
por: Aomar-Millán, Ismael Francisco, et al.
Publicado: (2023)

Proposal for the use of anakinra in acute respiratory distress secondary to COVID-19()
por: Muñoz-Jiménez, Alejandro, et al.
Publicado: (2021)

Interleukin-6 Blockade With Tocilizumab in Anakinra-Refractory Febrile Infection-Related Epilepsy Syndrome (FIRES)
por: Stredny, Coral M., et al.
Publicado: (2020)

Effectiveness of anakinra for tocilizumab-refractory severe COVID-19: A single-centre retrospective comparative study
por: de la Calle, Cristina, et al.
Publicado: (2021)

Hepatotoxicity of tocilizumab and anakinra in rheumatoid arthritis: management decisions
por: Mahamid, Mahmud, et al.
Publicado: (2011)

Anakinra/tocilizumab: Primary biliary cholangitis: case report
Publicado: (2021)

Could anakinra outmatch dexamethasone/tocilizumab in COVID-19?
por: Gupta, Rahul
Publicado: (2022)

Influence of DNA Mismatch Repair (MMR) System in Survival and Response to Immune Checkpoint Inhibitors (ICIs) in Non-Small Cell Lung Cancer (NSCLC): Retrospective Analysis
por: Olivares-Hernández, Alejandro, et al.
Publicado: (2022)

Hepatotoxicity due to tocilizumab and anakinra in rheumatoid arthritis: two case reports
por: Mahamid, Mahmud, et al.
Publicado: (2011)

Early identification of COVID-19 cytokine storm and treatment with anakinra or tocilizumab
por: Langer-Gould, Annette, et al.
Publicado: (2020)

Anakinra or tocilizumab for prevention of COVID-19 death? A big dilemma
por: Patoulias, Dimitrios, et al.
Publicado: (2021)

Comparison of Anakinra and Tocilizumab in Anticytokine Therapy in the Treatment of Coronavirus Disease-2019
por: Ozkan, Feyza, et al.
Publicado: (2022)

Refractory Sweet Syndrome Treated with Anakinra
por: Shahid, Zainab, et al.
Publicado: (2019)

Tocilizumab versus anakinra in COVID-19: results from propensity score matching
por: Arcani, Robin, et al.
Publicado: (2023)

Anakinra treatment for refractory cerebral autoinflammatory responses
por: Jang, Yoonhyuk, et al.
Publicado: (2022)

Comparison of anakinra and tocilizumab in management of severe COVID-19: a retrospective cohort study
por: KÜÇÜKŞAHİN, Orhan, et al.
Publicado: (2022)

Immune System Disorders, Cancer and Viral Infections: A New Treatment Opportunity for the Immune Checkpoint Inhibitors
por: Olivares-Hernández, Alejandro, et al.
Publicado: (2021)

Can emapalumab be life saving for refractory, recurrent, and progressive cytokine storm caused by COVID-19, which is resistant to anakinra, tocilizumab, and Janus kinase inhibitors
por: Cure, Erkan, et al.
Publicado: (2021)

Anakinra after treatment with corticosteroids alone or with tocilizumab in patients with severe COVID‑19 pneumonia and moderate hyperinflammation. A retrospective cohort study: reply
por: Aomar-Millán, Ismael Francisco, et al.
Publicado: (2021)

Short-term outcomes in patients with systemic juvenile idiopathic arthritis treated with either tocilizumab or anakinra
por: Kearsley-Fleet, Lianne, et al.
Publicado: (2019)

Anakinra in Refractory Multisystem Inflammatory Syndrome in Children (MIS-C)
por: Bhat, Chandrika S., et al.
Publicado: (2021)

Anakinra utilization in refractory pediatric CAR T-cell associated toxicities
por: Diorio, Caroline, et al.
Publicado: (2022)

Anakinra after treatment with corticosteroids alone or with tocilizumab in patients with severe COVID-19 pneumonia and moderate hyperinflammation. A retrospective cohort study
por: Aomar-Millán, Ismael Francisco, et al.
Publicado: (2021)

Statistical models to predict clinical outcomes with anakinra vs. tocilizumab treatments for severe pneumonia in COVID19 patients
por: Piconi, Stefania, et al.
Publicado: (2023)

Efficacy and secondary infection risk of tocilizumab, sarilumab and anakinra in COVID‐19 patients: A systematic review and meta‐analysis
por: Peng, Jingwen, et al.
Publicado: (2021)

Refractory Minimal Change Disease and Focal Segmental Glomerular Sclerosis Treated With Anakinra
por: Angeletti, Andrea, et al.
Publicado: (2021)

Dopamine Receptors and the Kidney: An Overview of Health- and Pharmacological-Targeted Implications
por: Olivares-Hernández, Alejandro, et al.
Publicado: (2021)

Tocilizumab in patients infected by SARS-CoV2()
por: Sancho, Milagros, et al.
Publicado: (2021)

Efficacy of Anakinra in Refractory Adult-Onset Still's Disease: Multicenter Study of 41 Patients and Literature Review
por: Ortiz-Sanjuán, Francisco, et al.
Publicado: (2015)

Resolution of Giant Coronary Aneurisms in a Child With Refractory Kawasaki Disease Treated With Anakinra
por: Gambacorta, Alessandro, et al.
Publicado: (2020)

The relationship between PARP inhibitors with the relapse and leukemisation of lymphomas: a case report
por: Navalón-Jiménez, Marta, et al.
Publicado: (2023)

An open label trial of anakinra to prevent respiratory failure in COVID-19
por: Kyriazopoulou, Evdoxia, et al.
Publicado: (2021)

Recovery of COVID-19 acute respiratory distress syndrome with tocilizumab: successful outcome in two critically ill patients
por: Cala-García, Juan David, et al.
Publicado: (2020)

EFFECT OF TOCILIZUMAB ON CARDIAC INJURY AND DYSFUNCTION IN COVID-19
por: Zafar, Amna, et al.
Publicado: (2021)

Tocilizumab administration in a refractory case of COVID-19
por: Dastan, Farzaneh, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ev4t45ldctp1mg8mula4t430sh